These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34678906)

  • 21. Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration.
    Hirono K; Maruyama-Inoue M; Yanagi Y; Kadonosono K
    PLoS One; 2024; 19(4):e0302295. PubMed ID: 38635732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Nakamura K; Akiyama H
    Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration.
    Brown DM; Nowik M; Bouillaud E; Dugel APU;
    Curr Eye Res; 2023 Jan; 48(1):44-50. PubMed ID: 36398628
    [No Abstract]   [Full Text] [Related]  

  • 25. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.
    Regillo C; Singh R; Hamilton R; Gedif K; Best C; Koh A; Holz FG
    Ophthalmologica; 2022; 245(5):403-412. PubMed ID: 35468601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
    Lally DR; Loewenstein A; Arnold JJ; Yang YC; Gedif K; Best C; Patel H; Tadayoni R; Heier JS
    Eye (Lond); 2023 Apr; 37(6):1242-1248. PubMed ID: 35597816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD.
    Lim JI; Niec M; Wong V
    Br J Ophthalmol; 2015 May; 99(5):618-23. PubMed ID: 25376617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment.
    Ueji N; Mase Y; Kubo A; Matsubara H; Chujo S; Matsui Y; Kondo M
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893574
    [No Abstract]   [Full Text] [Related]  

  • 31. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
    Wykoff CC; Brown DM; Maldonado ME; Croft DE
    Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.
    Musiał-Kopiejka M; Polanowska K; Dobrowolski D; Krysik K; Wylęgała E; Grabarek BO; Lyssek-Boroń A
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data.
    Radke NV; Mohamed S; Brown RB; Ibrahim I; Chhablani J; Amin SV; Tsang CW; Brelen ME; Raichand NS; Fang D; Zhang S; Dai H; Chen GLJ; Cheung CMG; Hariprasad SM; Das T; Lam DSC
    Asia Pac J Ophthalmol (Phila); 2023 Mar-Apr 01; 12(2):168-183. PubMed ID: 36971706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
    Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
    Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of recalcitrant neovascular wet age-related macular degeneration treated with Intravitreal Brolucizumab.
    Panigrahi PK
    Photodiagnosis Photodyn Ther; 2021 Sep; 35():102450. PubMed ID: 34303030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy.
    Ferrante N; Ritrovato D; Bitonti R; Furneri G
    BMC Health Serv Res; 2022 Apr; 22(1):573. PubMed ID: 35484540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
    Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
    Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.